Provided by Tiger Trade Technology Pte. Ltd.

KraneShares MSCI All China Health Care Index ETF

19.07
+0.00250.01%
Volume:14.29K
Turnover:273.72K
Market Cap:110.63M
PE:- -
High:19.22
Open:19.22
Low:19.05
Close:19.07
52wk High:21.88
52wk Low:14.38
Shares:5.80M
Float Shares:5.80M
Volume Ratio:0.36
T/O Rate:0.25%
Dividend:0.71
Dividend Rate:3.75%
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

Transcenta Holding Announces Extraordinary General Meeting

Reuters
·
Aug 25

Chinese Drugmaker Wuxi XDC's First-Half Revenue Rises on Project Expansion, Acquisition

Reuters
·
Aug 24

WuXi XDC FY26 H1 Net Profit Rises 9.7% to RMB 818 Million; Revenue Climbs 37% to RMB 3.7 Billion

Reuters
·
Aug 24

Nomura Adjusts CSPC Pharmaceutical Group's Price Target to HK$10.93 From HK$10.31, Keeps at Buy

MT Newswires Live
·
Aug 24

CSPC Pharmaceutical Group Stock Climbs 2.2% in Hong Kong, Outperforms Competitors

Dow Jones
·
Aug 24

Wuxi Biologics (Cayman) Stock Falls 4.7% in Hong Kong

Dow Jones
·
Aug 24

Daiwa Raises CSPC Pharma Target Price to HK$11.2 on In-Line Interim Results

Stock News
·
Aug 24

BofA Securities Lifts CSPC Pharma Target Price to HK$8.6 While Maintaining Underperform Rating

Deep News
·
Aug 23

UBS Lifts CSPC Pharma Price Target to HK$11.80, Reiterates Buy Rating

Deep News
·
Aug 23

Goldman Sachs Adjusts CSPC Pharma Target Price Upward While Retaining Buy Stance

Deep News
·
Aug 23

CSPC Pharmaceutical Group Limited Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

Simply Wall St.
·
Aug 23

China's Haohai Biological H1 Revenue Falls, Partly Hurt by End of Brighten Optix Distribution

Reuters
·
Aug 21

TOT Biopharm FY26 H1 Net Loss Swings to RMB 59 Million; Revenue Drops 49.7% to RMB 246 Million

Reuters
·
Aug 21

UOB Kay Hian Upgrades CSPC Pharmaceutical Group to Buy from Sell; Price Target is HK$11.50

MT Newswires Live
·
Aug 21

Goldman Sachs Raises CSPC Pharma Price Target to HK$12.56, Reaffirms Buy Rating

Stock News
·
Aug 21

Wuxi Biologics (Cayman) Stock Rallies 2.7% in Hong Kong

Dow Jones
·
Aug 21

CSPC Pharmaceutical Group Stock Falls 3.5% in Hong Kong, Underperforms Competitors

Dow Jones
·
Aug 21

美银证券上调石药集团目标价至8.6港元,维持“跑输大市”评级

Stock News
·
Aug 21

Akeso Says China NMPA Clears Phase I Trial for B7-H3 ADC Ak157d1 in Solid Tumors

Reuters
·
Aug 21

Akeso's Ak157d1 (B7-H3 ADC) Cleared for Phase I Trial in Solid Tumors, Adding a Third Differentiated ADC to Its Pipeline

THOMSON REUTERS
·
Aug 21